High-throughput screening of clinically approved drugs that prime nonviral gene delivery to human Mesenchymal stem cells

Table 4 Drug class average fold-changes for negative hits in each donor

Drug Class [total hits]	Concentration [μM]	# of hits		Transfection FC^a		Hoechst FC^b
Drug Class [total hits]	Concentration [μM]	D1	D2	D1	D2	D1	D2
Flavonoid [3]	100	1	2	−23	-18	2.0	1.1
	13	0	0	N.A.	N.A.	N.A.	N.A.
	1.7	0	0	N.A.	N.A.	N.A.	N.A.
	0.2	0	0	N.A.	N.A.	N.A.	N.A.
Antineoplastic [7]	100	2	1	−14	-2.7	0.9	0.5
	13	1	1	−2.4	-4.6	0.9	0.6
	1.7	2	0	−2.3	N.A.	0.9	N.A.
	0.2	0	0	N.A.	N.A.	N.A.	N.A.
Antibiotic [9]	100	4	4	− 5.8	-3.1	1.5	1.5
	13	0	1	N.A.	-2.9	N.A.	1.5
	1.7	0	0	N.A.	N.A.	N.A.	N.A.
	0.2	0	0	N.A.	N.A.	N.A.	N.A.
Antihypertensive [9]	100	3	4	− 3.3	-4.8	0.9	1.1
	13	1	1	− 2.2	-1.8	1.2	1.5
	1.7	0	0	N.A.	N.A.	N.A.	N.A.
	0.2	0	0	N.A.	N.A.	N.A.	N.A.

^aTransfection FCs were calculated by averaging transfection efficiency, EGFP cell-counts, and transgenic luciferase activity (RLU/mg) FC averages of hits from the same cluster and concentration for each donor. Transfection efficiency FCs were calculated from triplicate averages of EGFP cell-counts normalized to Hoechst-counts, relative to the same measurement averaged from the VCs in each compound’s respective plate. EGFP cell count FCs were calculated from triplicate averages of EGFP cell-counts, relative to the same measurement averaged from the VCs in each compound’s respective plate. RLU/mg FCs were calculated from triplicate averages of luciferase luminescence, in relative light units (RLUs), normalized to total protein, relative to the same measurement averaged from the VCs in each compound’s respective plate
^bHoechst FCs of hits from the same cluster and concentration were averaged for each donor. Hoechst FCs were calculated from triplicate averages of total cell-count (determined by Hoechst-count), relative to the same measurement averaged from the VCs in each compound’s respective plate

ISSN: 1754-1611